In adults with ATTR cardiac amyloidosis, patisiran...

In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 mo.

Abstract

SOURCE CITATION: Maurer MS, Kale P, Fontana M, et al; APOLLO-B Trial Investigators. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389:1553-1565. 37888916.

Authors

Masri A; Van Spall HGC

Journal

Annals of Internal Medicine, Vol. 177, No. 3,

Publisher

American College of Physicians

Publication Date

March 1, 2024

DOI

10.7326/j24-0004

ISSN

1056-8751

Associated Experts

Harriette Van Spall

Associate Professor, FHSMED

Visit profile

Labels

In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 mo.

Abstract

Authors

Journal

Publisher

Publication Date

DOI

ISSN

Associated Experts

Labels

Fields of Research (FoR)

Sustainable Development Goals (SDG)

Medical Subject Headings (MeSH)

Contact the Experts team